Poor Hemorrhagic Stroke Outcomes During the COVID-19 Pandemic Are Driven by Socioeconomic Disparities: Analysis of Nationally Representative Data

Short Title: Effect of COVID-19 on Stroke Hemorrhagic Outcomes

Abdulaziz T. Bako MBBS MPH PhD¹; Thomas Potter PhD,¹ Alan Pan MS,² Karim A. Borei MD MBBCh;¹ Taya Prince BS,¹ Gavin Britz MD MPH,¹ Farhaan S. Vahidy* PhD MBBS MPH;^{1,2,3}

- 1. Department of Neurosurgery, Houston Methodist, Houston, TX.
- 2. Center for Health Data Science and Analytics, Houston Methodist, Houston, TX
- Department of Population Health Sciences, Weill Cornell Medical College, New York, NY

Corresponding Author:

Abdulaziz T. Bako, PhD MBBS MPH

7550 Greenbriar Drive, Suite 4.73

Houston, TX 77030

atbako@houstonmethoist.org

Conflict of Interest: The authors declare no conflict of interest

Keywords: Intracerebral Hemorrhage, Subarachnoid Hemorrhage, COVID-19, Socioeconomic Disparities, Social Determinants of Health.

Abstract

2 Background

1

3 Nationally representative data demonstrating the impact of the COVID-19 pandemic on

4 hemorrhagic stroke outcomes are lacking.

5 Methods

- 6 In this pooled cross-sectional analysis, we used the National Inpatient Sample (2016-
- 7 2020) to identify adults (>=18 years) with primary intracerebral hemorrhage (ICH) or
- 8 subarachnoid hemorrhage (SAH). We fit segmented logistic regression models to
- 9 evaluate the differences in the rates of in-hospital outcomes (in-hospital mortality, home
- 10 discharge, and receiving neurosurgical procedures) between the pre-pandemic
- 11 (January 2016-February 2020) and pandemic periods (March 2020-December 2020).
- 12 We used multivariable logistic regression models to evaluate the differences in mortality
- 13 between patients admitted from April to December 2020, with and without COVID-19,
- and those admitted during a similar period in 2019. Stratified analyses were conducted
- among patients residing in low and high-income zip codes and among patients with
- 16 extreme loss of function (E-LoF) and those with minor to major loss of function (MM-
- 17 LoF).

18 Results

- 19 Overall, 309,965 ICH patients (mean age [SD]: 68[14.8], 47% female, 56% low-income)
- and 112,210 SAH patients (mean age [SD]: 60.2[15.4], 62% female, 55% low-income)
- were analyzed. Pre-pandemic, ICH mortality was decreasing by ≈1% per month
- 22 (adjusted odds ratio, 95% confidence interval: 0.99, 0.99-1.00). However, during the
- pandemic, the overall ICH mortality rate increased by $\approx 2\%$ per month (1.02, 1.00-1.02)
- and $\approx 4\%$ per month among low-income patients (1.04, 1.01-1.07). However, there was
- no change in trend among high-income ICH patients during the pandemic (1.00, 0.97-
- 1.03). Patients with comorbid COVID-19 in 2020 had significantly higher odds of
- 27 mortality compared to the 2019 comparison cohort, overall (ICH: 1.83, 1.33-2.51; SAH:
- 28 2.76, 1.68-4.54), and among patients with MM-LoF (ICH: 2.15, 1.12-4.16; SAH: 5.77,
- 1.57-21.17). However, patients with E-LoF and comorbid COVID-19 had similar
- 30 mortality rates with the 2019 cohort.

31 Conclusion

- 32 Sustained efforts are needed to address socioeconomic disparities in healthcare
- access, quality, and outcomes during public health emergencies.

34

35 Introduction

- The global outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2,
- resulted in a pandemic that disrupted healthcare, especially among vulnerable
- populations.^{1,2} COVID-19 infection may worsen vascular diseases by disrupting the
- coagulation cascade and exacerbating inflammatory responses.^{3,4} Although prior
- 40 studies have shown that COVID-19 increases the risk of poor outcomes among patients
- 41 with ischemic stroke,^{5,6} there is a paucity of nationally representative data on the
- 42 potential impact of the COVID-19 pandemic on the trends in hemorrhagic stroke
- 43 (intracerebral hemorrhage [ICH] and subarachnoid hemorrhage [SAH]) outcomes.
- 44 Therefore, we used the largest publicly available all-payer inpatient healthcare database
- in the United States (US), the National Inpatient Sample (NIS), to evaluate the
- 46 differences in the trends of hemorrhagic stroke outcomes before and after the COVID-
- 47 19 pandemic.

48 Methods

- 49 Ethics Statement
- 50 Because this research utilized publicly available and de-identified data, it is considered
- 51 exempt from review by the Houston Methodist Institutional Review Board. We followed
- 52 the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)
- 53 guidelines.⁷

54 Data availability

- 55 After completing a data use agreement training, qualified researchers can obtain NIS
- 56 data through the Health Care Utilization Project's central distributor
- 57 (<u>https://www.distributor.hcup-us.ahrq.gov/</u>).
- 58 Study Design, Data Source, and Case Identification
- 59 NIS represents over 90% of all US hospitalizations.⁸ In this pooled cross-sectional
- 60 study, we used validated International Classification of Disease Tenth Revision (ICD-10)
- codes to identify adults (≥ 18 years) discharged with a principal diagnosis of ICH (ICD-

10 codes: I61.0-I61.6 and I61.8-I61.9) or SAH (I60) from 2016 to 2020. We excluded patients with concurrent diagnoses of head trauma and/or arteriovenous malformation, as well as patients with missing age information. Also, we excluded patients transferred to an acute care hospital to avoid double counting the same patient, as the unit of observation in the NIS database is a hospitalization encounter and not an individual patient. Among the ICH cohort, we additionally excluded patients with co-occurring diagnoses of intracranial aneurysms and brain malignancy.

69 Race/ethnicity was coded as non-Hispanic White (NHW), non-Hispanic Black (NHB). Asian American and Pacific Islanders (AAPI), Hispanic, and Others (including Native 70 71 Americans and Others). Income status was defined according to the income guartile of the patient's zip code, with quartiles 1 and 2 considered as low-income and quartiles 3 72 73 and 4 considered as high-income zip codes. The National Institutes of Health Stroke Scale (NIHSS) score was only available for less than one-third (20.7%) of our analysis 74 75 sample; therefore, we utilized the administratively derived All Patient Refined Diagnosis Related Group (APR-DRG) severity of illness scores to assess disease severity. We 76 77 further grouped patients, based on their APR-DRG severity of illness score, into those with extreme loss of function (E-LoF) and those with minor to major loss of function 78 79 (MM-LoF).⁹ COVID-19 status was identified using ICD-10 code U07.1. This ICD code was released in late March of 2020 and is reserved for laboratory-confirmed cases of 80 SARS-CoV-2. 81

- 82 The primary outcome is in-hospital mortality and secondary outcomes include home
- discharge, receiving craniotomy (for ICH cohort), and undergoing coiling or clipping (for
- 84 SAH cohort).

85 Statistical Analyses

Descriptive statistics were reported using means and percentages. We used a series of
univariable logistic regression models to evaluate the differences in the clinical and
sociodemographic characteristics of patients admitted before the official declaration of
national emergency response to the COVID-19 pandemic (January 2016 - February
2020) (pre-pandemic period), and patients admitted during and after the emergency
declaration (March 2020 – December 2020) (pandemic period). Furthermore, we fit a

series of unadjusted and adjusted segmented logistic regression models¹⁰ (details in 92 supplemental methods) to evaluate the differences in the rates (slope) of in-hospital 93 outcomes between the pre-pandemic and pandemic periods, as crude/adjusted odds 94 ratios (OR/aOR) and 95% confidence interval (CI). The multivariable models included 95 adjustments for sociodemographic factors (age, sex, race/ethnicity, and insurance type), 96 clinical factors (hypertension, diabetes, congestive heart failure, obesity, renal failure, 97 Charlson Comorbidity Index, and APR-DRG severity of illness score), and hospital-98 related factors (urban/rural location of hospital, teaching status of hospital, and hospital 99 bed size). To evaluate whether income modifies the association of the pandemic with 100 ICH and SAH outcomes, we performed stratified analyses among patients residing in 101

102 low-income and high-income zip codes.

In a second series of analyses, we used multivariable logistic regression models to evaluate the sociodemographic and clinical factors independently associated with having comorbid COVID-19 infection and ICH or SAH among a cohort of patients admitted April to December 2020. In a third and final series of analyses, we used multivariable logistic regression models to assess the differences in mortality, between

- 108 ICH and SAH patients admitted from April to December 2020, with and without COVID-
- 109 19, and patients admitted during a similar period in 2019. We performed stratified
- 110 multivariable analyses among patients with MM-LoF and those with E-LoF. The
- 111 confounding variables in all adjusted models were selected based on prior evidence
- demonstrating their association with hemorrhagic stroke outcomes. All analyses were
- 113 conducted with 0.05 level of significance, utilizing Stata version 17.¹¹.

114 **Results**

Overall, 309,965 ICH patients (mean age [SD]: 68 [14.8], 47% female, 56% residing in
low-income zip codes) and 112,210 SAH patients (mean age [SD]: 60.2 [15.4], 62%
female, 55% residing in low-income zip codes) were included (Table S1). Among the
ICH cohort, 259,535 patients (mean age [SD]: 68 [14.8], 47% female, 55% residing in
low-income zip codes) were admitted during the pre-pandemic period and 50,430
patients (mean age [SD]: 67 [14.9], 46% female, 57% residing in low-income zip codes)
were admitted during the pandemic period. Among the SAH cohort, 93,855 patients

(mean age [SD]: 60.2 [15.4], 62% female, 56% residing in low-income zip codes) were

- admitted during the pre-pandemic period and 18,355 patients (mean age [SD]: 60.1
- 124 [15.3], 60% female, 57% residing in low-income zip codes) were admitted during the
- pandemic period. In univariate analyses, ICH patients admitted during the pandemic
- period were significantly more likely to be insured via Medicaid (OR, 95% CI: 1.23, 1.14
- -1.33) or private (1.08, 1.01 1.15) insurance (vs. Medicare), have heart failure (1.13,
- 128 1.06 1.20), obesity (1.30, 1.21 1.39), renal failure (1.07, 1.01 1.13) and higher
- 129 Charlson Comorbidity Index (1.03, 1.02 1.04) (Table S1).
- 130 In the pre-pandemic period, the mortality rate among ICH patients was decreasing by
- approximately 1% per month (aOR, 95% CI: 0.99, 0.99 1.00; p-value < 0.001).
- However, the overall mortality rate during the pandemic period increased by about 2%
- per month relative to the monthly rate in the pre-pandemic period (1.02, 1.00 1.02, p-
- value < 0.05) (See figure 1A and Table 1). Among patients residing in low-income zip
- codes, mortality rate during the pandemic period increased by 4% per month relative to
- the pre-pandemic period (1.04, 1.01 1.07). However, there was no significant change
- in mortality trend during the pandemic period among ICH patients residing in high-
- income zip codes (1.00, 0.97 1.03) (Table 1 and Figure 1B and 1C). Also, there was
- no significant change in the trend for other ICH outcomes or any SAH outcomes during
- 140 the pandemic period (vs. pre-pandemic).
- Among patients admitted between April and December 2020 (ICH: 44,405 without
- 142 COVID-19 and 935 with COVID-19; SAH: 16,205 without COVID-19 and 395 with
- 143 COVID-19), males (aOR, 95% CI: 1.42, 1.03 1.97) (vs. females), NHB (1.94, 1.28 –
- 144 2.95), Hispanics (3.59, 2.29 5.64) and the "Other" race/ethnicity category (3.66, 2.16 –
- 145 6.19) (vs. NHW) had significantly higher odds of having comorbid ICH and COVID-19,
- 146 while Hispanics (vs. NHW) have significantly higher odds of having comorbid SAH and
- 147 COVID-19 (4.73, 2.88 7.79) (Figure 2).
- 148 In multivariable analyses, ICH and SAH patients with comorbid COVID-19 had a
- significantly higher likelihood of mortality compared to patients admitted between April
- to December 2019, overall (aOR, 95% CI: 1.83, 1.33 2.51 for ICH; and 2.76, 1.68 –
- 4.54 for SAH) and among patients with MM-LoF (2.15, 1.12 4.16 for ICH; and 5.77,

152 1.57 – 21.17 for SAH). However, among patients with E-LoF, there was no significant

- difference in the likelihood of mortality between ICH and SAH patients with comorbid
- 154 COVID-19 admitted between April to December 2020 and patients admitted during a
- similar period in 2019. Furthermore, among ICH and SAH patients without comorbid
- 156 COVID-19, the likelihood of mortality was similar across the 2020 and 2019 April to
- 157 December cohorts.
- 158 Tables S2 and S3 provide details of the univariate comparisons of the characteristics of
- 159 ICH and SAH patients with comorbid COVID-19 (admitted between April to December
- 160 2020) and patients admitted during a similar period in 2019 (model group 1). Tables S2
- and S3 also provide univariate comparisons of ICH and SAH patients admitted between
- April and December 2020 with and without comorbid COVID-19 (model group 2).

163 **Discussion**

We evaluated the association of the COVID-19 pandemic with ICH and SAH in-hospital 164 outcomes in a nationally representative sample. Relative to the pre-pandemic period, 165 we observed a significant increase in the monthly rate of in-hospital mortality among 166 ICH patients during the pandemic period. This increase was primarily driven by ICH 167 patients residing in low-income zip codes, whereas no change in mortality was 168 observed among patients residing in high-income zip codes. We also demonstrate that 169 comorbid COVID-19 was associated with higher likelihood of mortality among ICH and 170 SAH patients with MM-LoF, but not among patients with E-LoF. 171

Similar to a previous report,¹² our analyses demonstrate that ICH mortality was 172 significantly declining during the pre-pandemic period. However, this trend was reversed 173 174 during the pandemic period, particularly among patients residing in low-income zip codes. Relative to the pre-pandemic period, the overall ICH mortality rate increased by 175 2% per month in the pandemic period. This acceleration of mortality rate seems to be 176 largely driven by patients residing in low-income zip codes, among whom ICH mortality 177 rate increased by 4% per month during the pandemic period, whereas no significant 178 179 change in mortality was observed among patients residing in high-income zip codes during the pandemic period. These findings suggest that the COVID-19 pandemic may 180 have slowed down the sustained improvement in ICH mortality observed during the pre-181

pandemic period, particularly among the low-income population. Though our analyses 182 do not definitively outline the reasons for disparate COVID-19 associated ICH 183 outcomes; higher comorbidity burden, lack of access, awareness, and even disparities 184 in care (including delayed care) may be postulated as potential drivers of such 185 disparities. Most importantly, our analyses are yet another demonstration of the 186 pandemic's disproportionate impact on vulnerable populations and highlight the need for 187 continued focus on uncovering and addressing the reasons for the now widely reported 188 socioeconomic disparities, particularly among patients with cerebrovascular disease.¹³ 189 Similar to prior smaller studies, we also report that hemorrhagic stroke (ICH and SAH) 190 patients with comorbid COVID-19 have significantly higher mortality compared to 191 patients without COVID-19.^{14,15} However, our data uniquely demonstrates, at the 192 national level, that comorbid COVID-19 was only associated with a higher likelihood of 193 in-hospital mortality among ICH and SAH patients with MM-LoF, whereas among 194 195 patients with E-LoF, COVID-19 status was not a significant driver of mortality. These findings have significant clinical relevance, and though we are limited from conducting a 196 197 clinically detailed exploration of the biological mechanisms driving the differences in mortality between hemorrhagic stroke patients with and without comorbid COVID-19, it 198 199 is reasonable to surmise, from previous studies, that a heightened systematic inflammatory response to the COVID-19 virus and it's directed end organ damage may 200 be potentiating these poor outcomes.¹⁶ However, further studies are needed to 201 elucidate the mechanisms driving poorer outcomes among hemorrhagic stroke patients 202 203 with comorbid COVID-19. Also, given that minority races/ethnicities are at a higher likelihood of having comorbid COVID-19, the findings of this research highlight the need 204 to further investigate the biological and environmental factors potentially driving 205 206 socioeconomic disparities in the association between COVID-19 and hemorrhagic stroke outcomes. 207

Our study has some limitations. First, this study covers only the first wave of the COVID-19 pandemic. Hence, future studies are needed to explore the trends in the subsequent waves of the pandemic as data for ensuing years become available. Secondly, our analysis may have missed COVID-19 patients who did not require or

receive in-hospital care for COVID-19 and potentially underestimated the prevalence of 212 COVID-19 among patients with ICH and SAH. Thirdly, we did not have detailed data on 213 214 the timing of hemorrhagic stroke and COVID-19 diagnosis. Finally, we did not have access to more granular clinical data, including patients' imaging data (to ascertain 215 hemorrhage location, volume, or other hemorrhage characteristics) and information on 216 the COVID-19 variants. Nevertheless, the insights provided by this study will be useful 217 in guiding the readiness of public health authorities to implement strategies addressing 218 sociodemographic disparities during public health emergencies. 219

220 Conclusions

The study found a significant acceleration of in-hospital mortality rate among ICH patients during the post-pandemic period, particularly among those residing in lowincome zip codes. Sustained efforts are needed to better understand the impact of the pandemic on stroke outcomes, particularly among vulnerable populations, as well as to address disparities in healthcare access, quality, and outcomes during public health emergencies.

227 Acknowledgments

Dr Bako had full access to all the data in the study and takes responsibility for the 228 integrity of the data and the accuracy of the data analysis. The content of this article is 229 based on data from the National Inpatient Sample (NIS) database, acquired from the 230 Agency for Healthcare Research and Quality's (AHRQ) Health Care Utilization Project 231 (HCUP). However, the content of this article does not necessarily reflect the views and 232 opinions of the AHRQ. Also, the AHRQ did not participate in the study's design, 233 234 implementation, data analysis, interpretation, nor manuscript preparation, review, 235 approval, or decision to submit the article for publication.

236 Disclosures

237 Authors declare no conflict of interest.

238

Figure 1: Segmented logistic regression of the effect of the COVID-19 pandemic on Intracerebral Hemorrhage Mortality, Overall (A) and disaggregated by low (B) and high (C) income residence status

242

243

244 Segmented logistic regression of the effect of the COVID-19 pandemic on Intracerebral Hemorrhage Mortality — unadjusted.

245 The solid lines run through pre-intervention and post-intervention unexponentiated coefficients (logit), while the dotted lines

represent what the post-pandemic trend would have been had the pandemic not occurred (counterfactual). The coefficients

247 used for this plot have not been adjusted for confounding variables; however, the reported p-values for the difference in slope

248 between pre-pandemic and post-pandemic period have been adjusted for confounding. A p-value < 0.05 indicates that there is

a significant change in trend (slope) between the pre-pandemic and post-pandemic mortality rate.

- Figure 2: Sociodemographic factors associated with having comorbid COVID-19 and ICH/SAH
- 252
- 253
- 254

255 Table 1: Effect of the COVID-19 Pandemic on ICH and SAH Mortality

Adjusted Models		
	ICH Mortality	SAH Mortality
Overall		
Pre-Covid Slope	0.99 (0.99 – 1.00) ***	1.00 (0.99 – 1.00) *
Post-Covid Slope	1.02 (1.00 – 1.04)	0.99 (0.96 – 1.02)
Difference between Pre- and Post-Covid Slope	1.02 (1.00 – 1.04) *	0.99 (0.96 - 1.03)
Low Income		
Pre-Covid Slope	1.00 (0.99 – 1.00) ***	1.00 (0.99 – 1.00)
Post-Covid Slope	1.04 (1.01 – 1.06) **	0.99 (0.95 – 1.03)
Difference between Pre- and Post-Covid Slope	1.04 (1.01 – 1.07) **	0.99 (0.95 – 1.04)
High Income		
Pre-Covid Slope	0.99 (0.99 – 1.00) ***	1.00 (0.99 – 1.00)
Post-Covid Slope	0.99 (0.96 – 1.02)	0.98 (0.93 – 1.03)
Difference between Pre- and Post-Covid Slope	1.00 (0.97 – 1.03)	0.99 (0.94 - 1.04)
Unadjusted Models		
	ICH Mortality	ICH Mortality
Overall		
Pre-Covid Slope	1.00 (1.00 – 1.00) ***	1.00 (0.99 – 1.00) *
Post-Covid Slope	1.01 (1.00 – 1.03)	1.00 (0.98 – 1.03)
Difference between Pre- and Post-Covid Slope	1.02 (1.00 – 1.03)	1.01 (0.98 – 1.03)
Low Income		
Pre-Covid Slope	1.00 (0.99 – 1.00) **	1.00 (0.99 – 1.00)
Post-Covid Slope	1.02 (1.00 – 1.05) *	1.00 (0.97 – 1.04)
Difference between Pre- and Post-Covid Slope	1.03 (1.01 – 1.05) *	1.01 (0.97 – 1.04)
High Income		
Pre-Covid Slope	1.00 (0.99 – 1.00) **	1.00 (0.99 – 1.00)
Post-Covid Slope	1.00 (0.97 – 1.02)	0.99 (0.95 – 1.04)
Difference between Pre- and Post-Covid Slope	1.00 (0.98 – 1.02)	1.00 (0.96 - 1.04)

256

* - p-value < 0.05; ** - p-value < 0.01; *** - p-value < 0.001

257 **References**

- Pujolar G, Oliver-Anglès A, Vargas I, Vázquez M-L. Changes in access to health services during the COVID-19 pandemic: A scoping review. *Int. J. Environ. Res. Public Health.* 2022;19:1749.
- Tannous J, Pan A, Bako A, Potter T, Jones SL, Janjan N, Smith ML, Seshadri S,
 Ory MG, Vahidy FS. COVID-19 associated disruptions in routine health care of
 people with mild cognitive impairment or dementia. *Alzheimers. Dement.* [Internet].
 2022;14. Available from: https://onlinelibrary.wiley.com/doi/10.1002/dad2.12323
- Vidal-Perez R, Brandão M, Pazdernik M, Kresoja K-P, Carpenito M, Maeda S,
 Casado-Arroyo R, Muscoli S, Pöss J, Fontes-Carvalho R, et al. Cardiovascular
 disease and COVID-19, a deadly combination: A review about direct and indirect
 impact of a pandemic. *World J. Clin. Cases*. 2022;10:9556–9572.
- Vasbinder A, Meloche C, Azam TU, Anderson E, Catalan T, Shadid H, Berlin H, Pan M, O'Hayer P, Padalia K, et al. Relationship between preexisting cardiovascular disease and death and cardiovascular outcomes in critically ill patients with COVID-19. *Circ. Cardiovasc. Qual. Outcomes*. 2022;15:e008942.
- de Havenon A, Zhou LW, Yaghi S, Frontera JA, Sheth KN. Effect of COVID-19 on acute ischemic stroke severity and mortality in 2020: Results from the 2020 National Inpatient Sample. *Stroke*. 2023;54:e194–e198.
- Qureshi AI, Baskett WI, Huang W, Shyu D, Myers D, Raju M, Lobanova I, Suri
 MFK, Naqvi SH, French BR, et al. Acute ischemic stroke and COVID-19: An
 analysis of 27 676 patients. *Stroke*. 2021;52:905–912.
- 279 7. Cuschieri S. The STROBE guidelines. *Saudi J. Anaesth.* 2019;13:S31–S34.
- NIS Database Documentation [Internet]. The Healthcare Cost and Utilization
 Project. [cited 2023 Feb 2];Available from: https://www.hcup us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
- Averill RF, Goldfield N, Hughes JS, Bonazelli J, McCullough EC, Steinbeck BA,
 Mullin R, Tang AM. ALL PATIENT REFINED DIAGNOSIS RELATED GROUPS
 (APR-DRGs) [Internet]. 07/2023 [cited 2023 Jun 15];Available from: https://hcup us.ahrq.gov/db/nation/nis/APR DRCs) (20Methodology(Quentionand Bibliography pdf
- 287 DRGsV20MethodologyOverviewandBibliography.pdf
- Mascha EJ, Sessler DI. Segmented regression and difference-in-difference
 methods: Assessing the impact of systemic changes in health care. *Anesth. Analg.* 2019;129:618–633.
- 11. Statacorp. Stata Statistical Software: Release 17 [Internet]. College Station, TX:
 StataCorp LLC.; 2021. Available from: https://www.stata.com/

- 12. Bako AT, Potter T, Pan A, Tannous J, Rahman O, Langefeld C, Woo D, Britz G,
 Vahidy FS. Geographic disparities in case fatality and discharge disposition among
 patients with primary intracerebral hemorrhage. *J. Am. Heart Assoc.* 2023;12:e027403.
- 13. Khanijahani A, lezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic
 review of racial/ethnic and socioeconomic disparities in COVID-19. *Int. J. Equity Health.* 2021;20:248.
- Ravindra VM, Grandhi R, Delic A, Hohmann S, Shippey E, Tirschwell D, Frontera
 JA, Yaghi S, Majersik JJ, Anadani M, et al. Impact of COVID-19 on the
 hospitalization, treatment, and outcomes of intracerebral and subarachnoid
 hemorrhage in the United States. *PLoS One*. 2021;16:e0248728.
- Leasure AC, Khan YM, Iyer R, Elkind MSV, Sansing LH, Falcone GJ, Sheth KN.
 Intracerebral hemorrhage in patients with COVID-19: An analysis from the COVID 19 cardiovascular disease registry. *Stroke*. 2021;52:e321–e323.
- Mitra J, Kodavati M, Provasek VE, Rao KS, Mitra S, Hamilton DJ, Horner PJ,
 Vahidy FS, Britz GW, Kent TA, et al. SARS-CoV-2 and the central nervous system:
 Emerging insights into hemorrhage-associated neurological consequences and
 therapeutic considerations. *Ageing Res. Rev.* 2022;80:101687.







